Drug Name: 

REGN2810*

Drug Description: 
PD-1 Antibody
Target Condition: 
Advanced cutaneous squamous cell carcinoma
Rank: 
50
Phase: 
Phase 2

NOW APPROVED IN THE UNITED STATES

Learn more